McCann KE - Search Results

1

Quantitative Predictors of Response to Neoadjuvant Chemotherapy on Dynamic Contrast-enhanced 3T Breast MRI.

Murakami W, Won Choi H, Joines MM, Hoyt A, Doepke L, McCann KE, Salamon N, Sayre J, Lee-Felker S. Murakami W, et al. Among authors: mccann ke. J Breast Imaging. 2022 Apr 15;4(2):168-176. doi: 10.1093/jbi/wbab095. J Breast Imaging. 2022. PMID: 38422427

2

Clinical Significance of Background Parenchymal Enhancement in Breast Cancer Risk Stratification.

Murakami W, Mortazavi S, Yu T, Kathuria-Prakash N, Yan R, Fischer C, McCann KE, Lee-Felker S, Sung K. Murakami W, et al. Among authors: mccann ke. J Magn Reson Imaging. 2024 May;59(5):1742-1757. doi: 10.1002/jmri.29015. Epub 2023 Sep 19. J Magn Reson Imaging. 2024. PMID: 37724902

3

Health Care Resource Utilization and Costs for Metastatic Breast Cancer Patients Newly Treated with Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Agents.

Mahtani R, Oestreicher N, Lalla D, Ogbonnaya A, Saundankar V, Willey J, Coutinho AD, McCann K. Mahtani R, et al. Clin Breast Cancer. 2022 Jun;22(4):e488-e496. doi: 10.1016/j.clbc.2021.11.013. Epub 2021 Dec 2. Clin Breast Cancer. 2022. PMID: 35067467 Free article.

4

Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.

Wainberg ZA, Singh AS, Konecny GE, McCann KE, Hecht JR, Goldman J, Chmielowski B, Finn RS, O'Brien N, Von Euw E, Price MM, Martinez D, Yonemoto L, Brennan M, Glaspy JA, Slamon DJ. Wainberg ZA, et al. Among authors: mccann ke. Clin Cancer Res. 2023 Jan 4;29(1):40-49. doi: 10.1158/1078-0432.CCR-22-1553. Clin Cancer Res. 2023. PMID: 36136304 Clinical Trial.

5

Advances in the use of PARP inhibitor therapy for breast cancer.

McCann KE, Hurvitz SA. McCann KE, et al. Drugs Context. 2018 Aug 8;7:212540. doi: 10.7573/dic.212540. eCollection 2018. Drugs Context. 2018. PMID: 30116283 Free PMC article. Review.

6

Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer.

McCann KE, Goldfarb SB, Traina TA, Regan MM, Vidula N, Kaklamani V. McCann KE, et al. NPJ Breast Cancer. 2024 Jan 19;10(1):8. doi: 10.1038/s41523-024-00614-w. NPJ Breast Cancer. 2024. PMID: 38242892 Free PMC article. Review.

7

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer.

Llinàs-Arias P, Íñiguez-Muñoz S, McCann K, Voorwerk L, Orozco JIJ, Ensenyat-Mendez M, Sesé B, DiNome ML, Marzese DM. Llinàs-Arias P, et al. Cancers (Basel). 2021 Aug 17;13(16):4139. doi: 10.3390/cancers13164139. Cancers (Basel). 2021. PMID: 34439290 Free PMC article. Review.

8

Updates in the treatment of HR+HER2- breast cancer.

Baclig NV, McCann KE. Baclig NV, et al. Among authors: mccann ke. Curr Opin Obstet Gynecol. 2024 Feb 1;36(1):57-63. doi: 10.1097/GCO.0000000000000925. Epub 2023 Dec 7. Curr Opin Obstet Gynecol. 2024. PMID: 38170552 Review.

9

Harnessing the immune system in the battle against breast cancer.

Nakasone ES, Hurvitz SA, McCann KE. Nakasone ES, et al. Among authors: mccann ke. Drugs Context. 2018 Feb 12;7:212520. doi: 10.7573/dic.212520. eCollection 2018. Drugs Context. 2018. PMID: 29456568 Free PMC article. Review.

10

Advances in Targeted Therapies for Triple-Negative Breast Cancer.

McCann KE, Hurvitz SA, McAndrew N. McCann KE, et al. Drugs. 2019 Jul;79(11):1217-1230. doi: 10.1007/s40265-019-01155-4. Drugs. 2019. PMID: 31254268 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

52 results

Search Page